dc.contributor.author |
Raynes, Jeremy |
en |
dc.contributor.author |
Young, Paul |
en |
dc.contributor.author |
Proft, Thomas |
en |
dc.contributor.author |
Williamson, DA |
en |
dc.contributor.author |
Baker, Edward |
en |
dc.contributor.author |
Moreland, Nicole |
en |
dc.date.accessioned |
2018-12-03T03:33:40Z |
en |
dc.date.issued |
2018-03 |
en |
dc.identifier.issn |
2049-632X |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/44799 |
en |
dc.description.abstract |
Group A Streptococcus (GAS) is a globally important human pathogen that causes a broad spectrum of disease ranging from mild superficial infections to severe invasive diseases with high morbidity and mortality. Currently, there is no vaccine available for human use. GAS produces a vast array of virulence factors including multiple adhesin molecules. These mediate binding of the bacteria to host tissues and are essential in the initial phases of infection. Prophylactic vaccination with adhesins is a promising vaccine strategy and many GAS adhesins are currently in development as vaccine candidates. The most advanced candidates, having entered clinical trials, are based on the M protein, while components of the pilus and a number of fibronectin-binding proteins are in pre-clinical development. Adhesin-based vaccines aim to induce protective immunity via two main mechanisms: neutralisation where adhesin-specific antibodies block the ability of the adhesin to bind to host tissue and opsonisation in which adhesin-specific antibodies tag the GAS bacteria for phagocytosis. This review summarises our current knowledge of GAS adhesins and their structural features in the context of vaccine development. |
en |
dc.format.medium |
Print |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
Pathogens and disease |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Animals |
en |
dc.subject |
Humans |
en |
dc.subject |
Streptococcus pyogenes |
en |
dc.subject |
Streptococcal Infections |
en |
dc.subject |
Bacterial Proteins |
en |
dc.subject |
Adhesins, Bacterial |
en |
dc.subject |
Streptococcal Vaccines |
en |
dc.subject |
Drug Evaluation, Preclinical |
en |
dc.subject |
Opsonin Proteins |
en |
dc.subject |
Clinical Trials as Topic |
en |
dc.subject |
Drug Discovery |
en |
dc.subject |
Antibodies, Neutralizing |
en |
dc.title |
Protein adhesins as vaccine antigens for Group A Streptococcus. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1093/femspd/fty016 |
en |
pubs.issue |
2 |
en |
pubs.volume |
76 |
en |
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
29718270 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
en |
pubs.subtype |
Review |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
739135 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Molecular Medicine |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Biological Sciences |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
dc.identifier.eissn |
2049-632X |
en |
pubs.record-created-at-source-date |
2018-05-03 |
en |
pubs.dimensions-id |
29718270 |
en |